The placebo response in social phobia

Journal of Psychopharmacology

Volumn 15, Issue 3, 2001, Pages 199-203

  Oosterbaan, Désirée B ^a   van Balkom, Anton J L M ^a   Spinhoven, Philip ^b   van Dyck, Richard ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Clinical trial; Double blind method; Placebo; Review; Social anxiety disorder; Social phobia

Indexed keywords

PLACEBO;

CLINICAL RESEARCH; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SOCIAL PHOBIA;

DOUBLE-BLIND METHOD; HUMANS; MULTICENTER STUDIES; PATIENT DROPOUTS; PHOBIC DISORDERS; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 0034862357     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988110101500314     Document Type: Review

References (41)

1. Paroxetine in social anxiety disorder: A randomized placebo-controlled study
2. Paroxetine in social phobia/social anxiety disorder
3. Placebo response in antidepressant drug trials
4. Placebo as a treatment for depression
5. Treatment of social phobia with clonazepam and placebo
6. Pharmacotherapy of panic disorder: Differential efficacy from a clinical viewpoint
7. Social phobia: The clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A placebo-controlled study
8. Pharmacologic treatment of obsessive compulsive disorder: Comparative studies
9. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder
10. Cognitive behavioral group therapy versus phenelzine therapy for social phobia
11. Moclobemide in social phobia: A double-blind, placebo-controlled clinical study
12. Placebo effect in randomized, controlled studies of acute bipolar mania and depression
13. Placebo control groups in randomized treatment trials: A statistician's perspective
14. Phenelzine versus atenolol in social phobia: A placebo-controlled comparison
15. Brofaromine for social phobia: A multicenter, placebo-controlled, double-blind study
16. The failure of placebo-controlled studies
17. Factors that influence the outcome of placebo-controlled antidepressant clinical trials
18. Moclobemide in social phobia: A controlled dose-response trial
19. Moclobemide in the treatment of social phobia
20. Cognitive therapy versus moclobemide in social phobia: A controlled study
21. Penny-wise and poundfoolish: The impact of measurement error on sample size requirements in clinical trials
22. Placebo response in anxiety disorders
23. Placebos, drug effects, and study design: A clinician's guide
24. A prospective, follow-along study of the course of social phobia
25. Patient-sampling in anxiety studies: Factors influencing response rate
26. Characteristics of panic disorder patients responding to placebo
27. Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression
28. Placebo-controlled trial of moclobemide in social phobia
29. The history of the double-blind procedure
30. Paroxetine treatment of generalized social phobia. A randomized controlled trial
31. Fluvoxamine treatment of social phobia: A double blind, placebo-controlled study
32. Placebo effects: Issues for clinical practice in psychiatry and medicine
33. Meta-analysis of cognitive-behavioral treatments for social phobia
34. How should efficacy be evaluated in randomized clinical trials of treatment for depression?
35. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications
36. Growing placebo response rate: The problem in recent therapeutic trials?
37. Clinical effects of buspirone in social phobia: A double-blind placebo-controlled study
38. Pharmacotherapy of social phobia: A controlled study with moclobemide and phenelzine
39. Proposed synthesis of placebo models